[logo] HealthTree Foundation
search person

Clinical Trial: Oral Ixazomib Maintenance for Non-Transplant Myeloma Patients

Posted: Feb 03, 2017
Clinical Trial: Oral Ixazomib Maintenance for Non-Transplant Myeloma Patients image

Ixazomib (Ninlaro) is an oral proteasome inhibitor approved in late 2015. It is now being used in a wide variety of treatment combinations and is also being evaluated as maintenance therapy. For patients who have received prior treatment and achieved some sort of major response (complete response, very good partial response or partial response), investigators are comparing ixazomib maintenance vs. no maintenance. The study will help investigators understand the impact of ixazomib as maintenance therapy and how it impacts progression free survival compared to no maintenance therapy. The study is open at 6 myeloma academic centers and is only for patients who have NOT undergone a stem cell transplant. To learn more, click the button below: Ixaxomib Maintenance Trial

Ixazomib (Ninlaro) is an oral proteasome inhibitor approved in late 2015. It is now being used in a wide variety of treatment combinations and is also being evaluated as maintenance therapy. For patients who have received prior treatment and achieved some sort of major response (complete response, very good partial response or partial response), investigators are comparing ixazomib maintenance vs. no maintenance. The study will help investigators understand the impact of ixazomib as maintenance therapy and how it impacts progression free survival compared to no maintenance therapy. The study is open at 6 myeloma academic centers and is only for patients who have NOT undergone a stem cell transplant. To learn more, click the button below: Ixaxomib Maintenance Trial

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

Thanks to our sponsors:
Sanofi logo
Adaptive logo
Pfizer logo
GSK logo
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.